Drugs / 68Ga-DOTA-FAPI
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04849247 | Apr 2021 → Apr 2024 | — | The First Affiliated Hospital of Xiamen University | Unknown | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04554719 | May 2020 → Dec 2023 | cancer | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-DOTA-FAPI | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04849247 ↗ |
| Modality | Diagnostic / imaging agent | “Gallium-68-labeled fibroblast activation protein inhibitor (68Ga-FAPI) is an emerging promising tumor tracer.” PMID 35657428 ↗ Jun 2022 |
| Route | Intravenous | “intravenous bolus injection” NCT04554719 ↗ |